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Iron Requirements of Infants and Toddlers
Magnus Domello¨f, yChristian Braegger, zCristina Campoy, §Virginie Colomb, jjTamas Decsi,
Mary Fewtrell, #Iva Hojsak, Walter Mihatsch, yyChristian Molgaard, §§Raanan Shamir,
jjjjDominique Turck, and Johannes van Goudoever, on Behalf of the ESPGHAN
Committee on Nutrition:
ABSTRACT
Iron deficiency (ID) is the most common micronutrient deficiency world-
wide and young children are a special risk group because their rapid growth
leads to high iron requirements. Risk factors associated with a higher
prevalence of ID anemia (IDA) include low birth weight, high cow’s-milk
intake, low intake of iron-rich complementary foods, low socioeconomic
status, and immigrant status. The aim of this position paper was to review the
field and provide recommendations regarding iron requirements in infants
and toddlers, including those of moderately or marginally low birth weight.
There is no evidence that iron supplementation of pregnant women improves
iron status in their offspring in a European setting. Delayed cord clamping
reduces the risk of ID. There is insufficient evidence to support general iron
supplementation of healthy European infants and toddlers of normal birth
weight. Formula-fed infants up to 6 months of age should receive iron-
fortified infant formula, with an iron content of 4 to 8 mg/L (0.6–1.2 mg 
kg1  day1). Marginally low-birth-weight infants (2000–2500 g) should
receive iron supplements of 1–2 mg  kg1  day1. Follow-on formulas
should be iron-fortified; however, there is not enough evidence to determine
the optimal iron concentration in follow-on formula. From the age of 6
months, all infants and toddlers should receive iron-rich (complementary)
foods, including meat products and/or iron-fortified foods. Unmodified
cow’s milk should not be fed as the main milk drink to infants before
the age of 12 months and intake should be limited to <500 mL/day in
toddlers. It is important to ensure that this dietary advice reaches high-risk
groups such as socioeconomically disadvantaged families and immigrant
families.
Key Words: anemia, breast-feeding, complementary feeding, cow’s milk,
follow-on formula, infant formula, infant, iron deficiency, iron
requirements, low birth weight, toddler
(JPGN 2014;58: 119–129)
I ron deficiency (ID) is the most common micronutrientdeficiency worldwide and young children are a special risk
group because their rapid growth leads to high iron requirements.
Risk factors associated with a higher prevalence of ID anemia
(IDA) include low birth weight, high cow’s-milk intake, low intake
of iron-rich complementary foods, low socioeconomic status, and
immigrant status (1–5).
Ten years ago, the European Society for Pediatric Gastro-
enterology, Hepatology, and Nutrition (ESPGHAN) Committee on
Nutrition (CoN) published a commentary on iron requirements in
early childhood, concluding that there was a lack of evidence
regarding the health effects of different iron intakes (6). That
comment did not include a recommendation regarding iron intakes.
The aim of this position paper is to review the field (see
summary in Table 1) and provide recommendations regarding iron
requirements of infants and toddlers (1–3 years of age), including
those of moderately or marginally low birth weight. Recommen-
dations for infants with a birth weight <1800 g have been pre-
viously published by the ESPGHAN CoN (7).
Relevant publications were identified from the databases of
PubMed, ISI Web of Science, and the Cochrane Library up to
March 2013. A comprehensive review of all randomized controlled
trials of iron interventions in infants and toddlers was performed.
DEFINITION OF ID AND IDA
ID is conventionally considered to develop in 3 stages: iron
depletion, iron-deficient erythropoiesis, and IDA, which is defined
as the combination of ID and anemia (low hemoglobin [Hb]). In the
first stage, body iron stores are reduced, which is typically
measured using serum ferritin. This biomarker has been shown
to closely parallel the size of body iron stores in adults, as measured
by bone marrow staining or repeated phlebotomy. No similar
validation studies have been performed in infants or toddlers.
Serum ferritin is an acute-phase reactant, limiting its usefulness
for the diagnosis of ID in states of infection or inflammation.
Measurements of serum iron alone provide little useful information
with regard to iron status because of the considerable hour-to-hour
and day-to-day variation. Transferrin saturation (the ratio between
serum iron and transferrin) is a more reliable marker than serum
iron and will decrease in the first or second stage of ID. However,
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ferritin is more commonly used than transferrin saturation as a
marker of iron depletion.
In the second stage of ID, iron-deficient erythropoiesis,
soluble transferrin receptors will increase in plasma as a marker
of increased iron needs in body tissues. Furthermore, zinc pro-
toporphyrin in red blood cells will increase, whereas the concen-
tration of hemoglobin in reticulocytes will decrease. In the third
stage of ID, IDA, the blood hemoglobin concentration will be
reduced and red cell morphology will be affected; the mean cell
volume will decrease, and the red cell distribution width will
increase.
There are several novel indicators of ID that need further
evaluation in children, including reticulocyte hemoglobin and
hepcidin (8,9). Hepcidin is a newly characterized oligopeptide
that seems to be pivotal for iron metabolism and it has been shown
to be closely associated with iron status and iron intakes in infants
(10).
ID is usually defined using 1 of the available markers of
iron status. As discussed, there is a plethora of markers of iron status
and none of them is sufficiently validated in children. Furthermore,
reference ranges and cutoffs for the different iron status biomarkers
are poorly defined in young children and the use of cutoffs defined
for older ages is usually inappropriate for young children because of
the large physiological changes in iron status and red cell
morphology occurring during the first year of life (11).
The combination of Hb and ferritin is considered the most
sensitive measure of the effects of iron interventions in children and
adults (12). Globally, many prevalence studies of ID have been
based on hemoglobin measurements only, assuming that ID causes
approximately 50% of anemia cases worldwide (13,14); however,
this does not produce reliable estimates because there are many
other causes of anemia, the prevalence of which vary greatly
between populations. Age-specific cutoffs for iron status indicators,
including hemoglobin and ferritin, should be used for young
children (Table 2).
PREVALENCE OF ID AND IDA
Globally, it is estimated that approximately 25% of preschool
children have IDA (15). The prevalence of IDA in European infants
is typically <2% before the age of 6 months, approximately 2% to
3% at 6 to 9 months, and 3% to 9% at 1 to 3 years of age (16–18)
(4,19–21). Similarly, the prevalence of ID (usually defined as
serum ferritin <10–12 mg/L) is highest at 1 to 3 years of age,
whereas European prevalence figures usually vary between 5% and
20% (4,18–20).
THEORETICAL IRON REQUIREMENTS
Body composition studies in the 1950s showed that total
body iron at birth is approximately 75 mg/kg (22). In the neonate,
most of the body iron is found in hemoglobin, but a term, healthy,
normal birth weight infant also has some iron stores, corresponding
to approximately 25% of total body iron. When the newborn
emerges from the relatively hypoxic environment of the uterus
out into the oxygen-rich atmosphere, hemoglobin synthesis is halted
and the Hb falls from an average of 170 g/L to about 120 g/L during
the first 6 weeks of life (23). Because of recirculation of iron from
senescent erythrocytes, iron is transferred from hemoglobin to iron
stores, which thereby increase in size. During the following months,
as the baby continues to grow and expand its blood volume, iron is
transferred back from stores to the blood compartment, making the
normal infant self-sufficient with regard to iron until the infant has
doubled his or her birth weight, which occurs at about 4 to 6 months
of age in a term, normal-birth-weight infant (23). Thus, exclusive
breast-feeding during this period can meet infant iron requirements
despite the low concentration of iron in breast milk (0.3 mg/L).
Between 6 and 24 months of age, the infant becomes
dependent on additional dietary iron and, because of rapid growth,
iron requirements per kilogram body weight are higher than during
any other period of life. Using a factorial approach similar to the one
published by Oski et al (24), assuming an average body weight of
TABLE 1. Summary of conclusions
Definitions of IDA A combination of hemoglobin and ferritin is recommended. Age-specific cutoffs should be used,
see Table 2.
General prevalence of IDA in
European infants and toddlers
<2% before 6 mo, 2%–3% at 6–9 mo, and 3%–9% at 1–3 y of age
Theoretical iron requirements Low before 6 months of age
0.9–1.3 mg  kg1  day1 at 6–12 mo
0.5–0.8 mg  kg1  day1 at 1–3 y
Iron absorption Generally low, depends on diet, but infants and toddlers can upregulate absorption when iron
stores decrease
Health effects related to iron deficiency IDA in young children is associated with long-lasting poor neurodevelopment
Adverse effects of excessive iron Possibly poor growth, increased risk of infections, and even poor neurodevelopment
Iron supplementation of pregnant women Does not improve infant iron status in European setting
Delayed umbilical cord clamping Improves iron status of infants
Breast-fed infants <6 mo Iron supplements do not reduce IDA in populations with already low (<5%–10%) prevalence of
IDA at 6 months
Formula-fed infants <6 mo Iron-fortified formula prevents IDA and possibly improves neurodevelopment
Low-birth-weight infants <6 mo Iron supplements (1–3 mg  kg1  day1 depending on birth weight) prevent IDA and possibly
improve neurodevelopment
Follow-on formulas 6–12 mo Iron fortification prevents IDA. Conflicting evidence with regard to neurodevelopment
Complementary foods 4–12 mo Iron-rich complementary foods and avoidance of unmodified cow’s milk prevents IDA
Iron supplements 4–12 mo Prevents IDA and may improve neurodevelopment but only in populations with high (>10%)
prevalence of IDA at 6–12 mo of age
Toddlers (12–36 mo) Few studies, but iron-rich complementary foods and a restriction of unmodified cow’s-milk intake to
<500 mL may prevent IDA
IDA¼ iron-deficiency anemia.
ESPGHAN Committee on Nutrition JPGN  Volume 58, Number 1, January 2014
120 www.jpgn.org
Copyright 2013 by ESPGHAN and NASPGHAN. Unauthorized reproduction of this article is prohibited.
7.5 kg at 6 months and 12 kg at 24 months, a blood volume of
80 mL/kg, tissue iron of 7 mg/kg, and iron stores of 10 mg/kg at
24 months, it can be calculated that total body iron needs to double
from 300 to 600 mg between 6 and 24 months. Allowing for
physiological iron losses of 20 mg  kg1  day1, the theoretical
requirement of absorbed iron during this period is 0.076 mg  kg1 
day1, which corresponds to an iron intake of 0.76 mg  kg1 
day1, assuming an average bioavailability of 10%. After 2 years of
age and up to puberty, iron requirements per kilogram of body
weight are slightly lower because body growth is slower.
Different authorities recommended the following daily iron
intakes: 7.8 to 11 mg at 6 to 12 months, 5.8 to 9.0 mg at 1 to 3 years,
6.1 to 10 mg at 4 to 8, and 8 to 11 mg/d at 9 to 13 years,
corresponding to 0.9 to 1.3, 0.5 to 0.8, 0.3 to 0.5, and 0.2 to
0.3 mg  kg1  day1 (25–30).
IRON ABSORPTION
Because iron cannot be excreted from the body, intestinal
absorption of iron is strictly regulated. Some food components
promote nonheme iron absorption (ascorbic acid, citric acid, meat
proteins, and human milk), whereas others inhibit absorption
(phytates, polyphenols, calcium, and cow’s milk). Absorption
of nonheme iron from breast milk is usually assumed to be up
to 50% and absorption from infant formula and iron-fortified
complementary foods is usually assumed to be approximately
10% (23). Meat products contain heme iron, which has a bioa-
vailability of approximately 25% and meat also promotes non-
heme iron absorption (31); however, iron absorption is highly
dependent on the individual’s iron status. In a state of iron
sufficiency, hepcidin is produced in the liver, and circulating
hepcidin is believed to block basolateral iron release from enter-
ocytes by inhibiting the iron transporter ferroportin. In contrast, in
a state of ID, hepcidin levels decrease and intestinal iron absorp-
tion is increased. This regulation has been shown in animal
models (32) and recently also in human infants (10). In line with
this, it has been shown that infants have the ability to upregulate
iron absorption when iron requirements increase (33,34). This
ability of each individual to be able to adapt iron absorption to
iron status is likely to make infants more resistant to ID than the
factorial approach would predict and highlights the need for
intervention trials to determine iron requirements.
HEALTH EFFECTS RELATED TO ID
The main public health problem associated with ID in child-
hood is the risk of poor neurodevelopment; however, some other
physiological manifestations have been attributed to ID in young
children, including growth retardation and impaired immune
response. Even though a few studies have showed improved weight
or length gain after iron treatment of initially iron-deficient children
(35–37), most studies have found no overall positive effect of iron
on growth (38) and, indeed, some studies have shown a negative
effect of iron on growth in iron-replete infants (see below). Iron has
many important functions in the immune system, and ID has been
suggested to impair secretion of cytokines, and reduce bactericidal
macrophage activity and T-cell proliferation (39); however, it has
not been convincingly shown in clinical studies that ID increases the
risk of infections. On the contrary, iron supplements have in several
studies been associated with an increased risk of infections (see
below).
EFFECTS ON NEURODEVELOPMENT
Growth and development of the central nervous system is
rapid during the first years of life and iron is critical for this process.
The human brain almost triples its weight from birth to 3 years of
age and has at that age reached 85% of its adult size (40). Animal
studies have shown that iron is essential for several aspects of brain
development: myelination, monoamine neurotransmitter function,
neuronal and glial energy metabolism, and hippocampal dendrito-
genesis (41,42).
Several well-performed case-control studies in children have
shown a consistent association between IDA in infancy and long-
lasting poor cognitive and behavioral performance (43,44). A
seminal case-control study was performed in the 1980s by Lozoff
et al, in a cohort of 191 Costa Rican 12- to 23-month-old toddlers
who had varying degrees of ID. She observed that toddlers with IDA
(defined as Hb <100 g/L and a serum ferritin <12 mg/L in
combination with either a high zinc protoporphyrin or a low
transferrin saturation) attained poorer Bayley mental development
score by an average of 8 points and poorer Bayley psychomotor
development score by an average of 10 points compared with
nonanaemic children. Lower cognitive scores compared with con-
trols remained at 5 (45), 11 to 14 (46), and up to 19 years of age (47),
despite early iron therapy. These results were statistically adjusted
for environmental and family factors, but the possibility of residual
confounding by socioeconomic or nutritional factors cannot be
excluded. Other case-control studies have shown similar results
with regard to cognitive performance (48,49), latencies of evoked
potentials (50,51), and motor development (52). Children with IDA
also have been shown to have long-lasting behavioral problems,
including wariness, hesitance, and externalizing and internalizing
problems (53).
It has been suggested that ID without anemia may be
associated with poor cognitive/behavioral outcomes, but this has
not been sufficiently studied. In particular, there is a lack of dose-
response studies linking indicators of iron status as continuous risk
factors with later cognitive outcomes.
A meta-analysis of 17 randomized clinical trials in children
that included cognitive outcomes showed that iron supplementation
had a modest positive effect on mental development indices,
equivalent to 1.5 to 2 points of 100, measured at the end of the
intervention (54). This effect was more apparent for children who
were initially anemic or who had IDA, suggesting that iron supple-
ments have positive cognitive effects in iron-deficient children.
This meta-analysis showed a more pronounced effect in children
ages 7 years or older and no convincing evidence for an effect of
iron supplements on neurodevelopmental outcomes in children
younger than 2 years. This lack of effect in the youngest infants
may be because of irreversible effects of ID on the developing brain
or the fact that cognitive development and behavior are more
difficult to measure in young children.
TABLE 2. Suggested cutoffs for definition of anemia and low serum ferritin at different ages
0–1 wk 2 mo 4 mo 6–24 mo 2–5 y
Hb, g/L 135 90 105 105 110
s-Ferritin, mg/L 40 40 20 10–12 10–12
Exact cutoffs for ferritin will vary depending on the laboratory method used. Data adapted from references 11 and 116–119.
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A recent meta-analysis concluded that preventive iron
supplements in infancy have a positive effect on motor development
(55), although this conclusion was reached based on the data from
only 3 randomized controlled trials (56–58).
POSSIBLE ADVERSE EFFECTS OF IRON
It is important to note that iron is a potent pro-oxidant and
that iron, in contrast to most other nutrients, cannot be actively
excreted by humans (23). In adults, the risk of iron overload from
dietary iron is mainly limited to individuals with hereditary hemo-
chromatosis, a relative common disorder especially in northern
Europe, with a reported frequency of homozygosity for the C282Y
mutation of approximately 0.3% and even higher prevalences in
Ireland, the United Kingdom, and Scandinavia (59); however,
in children, the risk of iron overload must be considered also in
individuals without this genetic disposition. Iron supplementation
of iron-replete infants may have adverse effects, for example,
increased risk of infections and impaired growth (60). Increased
risk of severe infections seems to be restricted to malarious regions
(61), whereas the risk of impaired growth has been observed also in
European infants in one study, which reported a 0.6-SD difference
in length gain between 4 and 9 months of age (62). A negative effect
of iron supplements on growth in iron-replete young children has
been shown in some studies (62–65) but needs confirmation in
larger trials and has not yet been confirmed in meta-analyses (38).
Because high iron intakes may have adverse effects in iron-
replete infants, it is important to identify iron requirements in young
children and to identify risk groups that benefit from higher iron
intakes.
PREVENTION OF ID
Risk factors for ID and IDA in European infants and toddlers
include low birth weight, early cord clamping, male sex, low
socioeconomic status, low meat intake, low intake of iron-fortified
products (including infant formula and follow-on formula), and a
high intake of cow’s milk (4,18–20,66–68).
Suggested interventions for prevention of ID at different ages
include iron supplementation of pregnant women, delayed umbi-
lical cord clamping, iron supplementation of infants (iron drops),
iron-fortified formula, meat products, iron fortification of follow-on
formula and complementary foods, avoidance of cow’s milk,
and use of iron-fortified milks. The following is a review of the
available evidence from intervention trials regarding these different
approaches.
IRON SUPPLEMENTATION OF
PREGNANT WOMEN
Iron supplementation of pregnant women has been suggested
to improve iron status in the newborn; however, iron transport to the
fetus is an active process and the fetus may be protected from ID
even when the mother has mild or moderate IDA. A recent
systematic review (69) concludes that there is a lack of convincing
evidence that iron supplementation during pregnancy improves
infant iron status, even though improvement was reported by a
single study performed in an Nigerian population with an extremely
high prevalence of IDA (70).
The ESPGHAN CoN concludes that there is no convincing
evidence that iron supplementation of pregnant women in a Euro-
pean setting would improve infant iron status.
UMBILICAL CORD CLAMPING
The timing of umbilical cord clamping is of great importance
for the amount of blood transfused from the placenta to the newborn
and may therefore influence the risk of later ID and IDA. Studies in
the 1960s showed that in normal, term newborns held 10 cm below
the vaginal level, the placental transfusion during the first 3 minutes
of life increases the newborn’s blood volume on average by 32%
(71). These studies also showed that a similar transfusion occurs
when the baby is placed on the mother’s chest (71). A recent
European survey of policies at different delivery units showed large
differences in cord clamping times both between and within
countries (72). Early cord clamping has been suggested to reduce
the risk for maternal postpartum hemorrhage.
Andersson et al (67) randomized 400 term Swedish infants to
delayed (>3 minutes) or early (<10 seconds) cord clamping and
showed a significant effect on neonatal iron status and also a
significant reduction in the proportion of iron-deficient infants at
4 months of age (0.6% vs 5.7%, P¼ 0.01), without any increase in
neonatal jaundice or any other adverse effects. Furthermore, there
were no adverse effects on postpartum hemorrhage or the pro-
portion of accurate umbilical cord blood gas samples (73). These
results support the conclusions of a Cochrane analysis, based on
studies performed in low-income countries, which concluded that
late cord clamping improves infant iron status (74).
There is strong evidence that delayed cord clamping
improves the iron status of infants and no convincing evidence
that this has any adverse effects. Compared with dietary interven-
tions, this practice is also easy to implement on a population level.
The ESPGHAN CoN therefore recommends delayed cord clamping
for all newborns.
DIETARY INTERVENTION STUDIES
Breast-Fed Infants
Iron supplements (ie, iron drops) are usually not recom-
mended for healthy, term, breast-fed infants during the first months
of life; however, 2 recent studies have addressed this issue. In a
study by Friel et al, 77 term, normal-birth-weight, breast-fed
Canadian infants were randomized to receive iron supplements
(7.5 mg/day, corresponding to 1–2 mg  kg1  day1) or placebo
between 1 and 6 months of life (56). Infants in the iron group had
significantly higher Hb at 6 months (124 vs 116 g/L), but this
difference had disappeared at 12 months. The prevalence of IDA at
6 months was 14% (3/21 infants) in the placebo group versus 0% (0/
28) in the iron-supplemented group, but this difference was not
significant because of the low number of infants in the study. It is
notable that the IDA prevalence of 14% at 6 months in this study
was higher than in most other studies of exclusively breast-fed
infants. In a follow-up at 13 months of age, iron-supplemented
infants had significantly higher Bayley psychomotor development
index (PDI) (100 12 vs 93 9); however, a weakness with this
study was small sample size and high attrition; of the original
77 infants, only 37 were evaluated at 13 months. These results need
to be confirmed in an adequately powered study before they can
form the basis for recommendations.
Ziegler randomized 75 term, normal-birth-weight, breast-fed
infants to receive a multimicronutrient supplement with or without
iron (7 mg/day corresponding to 1–2 mg  kg1  day1) from 1 to
5.5 months of age (75). Infants receiving iron had significantly
higher plasma ferritin at 5.5 months, but there was no difference in
the primary outcome, which was serum ferritin at 9 months of age.
The prevalence of IDA at 6 months in this study was 3% (1/29)
versus none in the iron-supplemented group. In this trial, no
neurodevelopmental outcomes were included.
The ESPGHAN CoN concludes that there is no convincing
evidence that iron supplements should be provided to normal-birth-
weight, exclusively breast-fed infants during the first 6 months
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of life in populations with a low prevalence of IDA among
6-month-olds.
Formula-Fed Infants Up To 6 Months
The importance of iron fortification of infant formula for the
prevention of IDA in infants was demonstrated in the 1950s (76)
and has since been confirmed (77). In 1994, Moffatt et al published
a comprehensive study in which 283 Canadian infants from extre-
mely low-income families were randomized to an iron-fortified
infant formula (12.8 mg/L) or a nonfortified formula (1.1 mg/L of
iron) from <2 to 15 months of age (58). At 6 months, infants
receiving iron-fortified formula had significantly higher mean Hb
(113.5 vs 107.7 g/L) and serum ferritin (26.8 vs 15.7 mg/L). There
was a significantly lower proportion of anemia (Hb <110 g/L) at
6 months in the iron-fortified group (8% vs 28%, P< 0.001). At 9,
12, and 15 months of age, these differences in iron status remained
but became more attenuated with time. Neurodevelopment was
assessed using the Bayley scales of infant development at 6, 9, 12,
and 15 months of age. The PDI was similar between groups at
6 months but fell in the unfortified group at 9 and 12 months with a
trend toward recovery at 15 months. At 12 months, mean (SD)
PDI among infants in the iron-fortified group was 100.5 14.1 as
compared with 94.2 12.6 in the unfortified group, P¼ 0.002.
There was no significant difference in the mental development
index at any time point. This study confirms the importance of iron
fortification of infant formula, even though the population of poor
infants with a high prevalence of anemia at 6 months even in
the iron-fortified group is not representative of the present
European population.
Owing to the much lower bioavailability of iron from infant
formula compared with breast milk, infant formulas have tradition-
ally been fortified to higher iron concentrations than in breast milk;
however, there has been a long-standing controversy regarding
which is the optimal level of iron fortification of infant formulas;
present American guidelines suggest 10 to 12 mg/L (78), whereas
the ESPGHAN-coordinated global standard recommends 0.3 to
1.3 mg/100 kcal, corresponding to 2 to 8.5 mg/L (79). As a
comparison, the iron content of breast milk is approximately
0.3 mg/L (80). The higher level of 12 mg/L is based on the
theoretical iron requirements from 0 to 12 months, but does not
take into account that the iron requirements during the first 6 months
of life are extremely low, as explained above. The lower level of
2 mg/L is based on the iron content in breast milk and the assumed
difference in iron bioavailability between breast milk and infant
formula, but this level has not yet been shown to be safe in
sufficiently powered intervention trials.
A few studies have compared the effects of different levels of
iron fortification of infant formula during the first 6 months of life.
In 1993, Bradley et al (81) randomized 347 healthy US infants to
receive infant formulas containing 7.4 or 12.7 mg/L of iron from
<2 to 12 months of age. There was no difference in Hb or serum
ferritin between groups at 6 months of age.
In 1994, Lo¨nnerdal and Hernell (82) randomized 50 Swedish
infants to 5 different intervention groups. Forty of the infants
received formulas with iron contents of 3.8 to 4.7 mg/L and
10 received a formula with an iron content of 6.9 mg/L. The
intervention lasted from <2 to 6 months of age. At 6 months, there
were no differences between high- and low-iron formula groups in
Hb or ferritin and no infant had ferritin <12 mg/L.
During the last decade, 2 studies have been performed using
even lower levels of iron fortification during the first 6 months of
life. In a British study, 100 healthy, term, normal-birth-weight
infants were randomized to receive formula with either 5 or
<1 mg/L of iron from the first week of life until 3 months of
age (83). There was no difference in Hb, ferritin, or any other iron
status variable between the groups at 3 or 12 months of age. In a
Swedish study, 43 term, normal-birth-weight infants were random-
ized to different infant formulas with iron concentrations ranging
from 2 to 4 mg/L from 1 to 6 months of age (84). No significant
difference in iron status was observed at 6 months; however, neither
of these studies was powered to study effects on ID or IDA. Even
though these studies suggest that iron concentrations lower than
those commonly used may be sufficient during the first few months
of life, no conclusion can be made regarding whether such low iron
concentrations will effectively prevent ID in the European popu-
lations.
Presently, most standard infant formulas in Europe have iron
concentrations of 4 to 8 mg/L. Based on the above evidence and the
low prevalence of IDA at 6 months in Europe, the ESPGHAN CoN
considers this practice safe and effective, but there is clearly a need
for sufficiently powered randomized controlled studies to better
determine the appropriate level of iron in infant formulas, which
may very well be lower than this range.
Low-Birth-Weight Infants
Low birth weight (LBW), defined as birth weight<2500 g, is
a major public health problem. In 2009, UNICEF estimated the
global prevalence to be 14% and local prevalence varies between
5% (Sweden) and 28% (India) (85). LBW is associated with
increased neonatal mortality and morbidity and is also an important
risk factor for lifelong health problems, including cognitive and
behavioral problems (86). LBW infants include both term, small-
for-gestational-age infants and preterm infants. Most LBW infants
have only marginally or moderately LBW (1500–2500 g). Infants
in this weight interval rarely require neonatal intensive care, and
clinical practice regarding iron supplementation of these infants is
highly variable (87). LBW infants have lower total body iron at
birth and a more rapid relative growth rate, leading to high iron
requirements even before 6 months of age. Using a similar factorial
calculation as above, an infant with a birth weight of 2000 g will
theoretically need at least 1 mg  kg1  day1 of dietary iron
between 6 weeks and 6 months of life.
There are relatively few published randomized intervention
trials comparing different doses of iron supplements or fortification
of human milk or formula given to LBW infants.
A meta-analysis has shown that prophylactic iron (supple-
ments or iron-fortified formula) given to LBW infants, with birth
weights 1500 to 2500 g, leads to significantly reduced incidence of
anemia at 6 months (88). Most of these studies used an enteral iron
dose of 2 mg  kg1  day1.
There are even fewer studies comparing different amounts of
iron given to LBW infants. In a study by Friel et al, 58 infants with
an average birth weight of 1500 g were randomized to different
infant formulas resulting in iron intakes of 3 to 6 vs 2 to 3 mg  kg1 
day1 up to 9 months of age (89). There was no difference in anemia
or neurodevelopment at 12 months; however, the high-iron group
had higher glutathione peroxidase concentrations (a marker of
oxidative stress), lower plasma zinc and copper concentrations,
and a higher number of respiratory tract infections, suggesting
possible adverse effects with higher iron intakes.
In a recent trial, Berglund et al randomized 285 marginally
LBW Swedish infants (2000–2500 g) to iron supplements at the
following doses: 0 (placebo), 1 or 2 mg  kg1  day1, given from
6 weeks to 6 months of age. In this population, iron supplements at a
dose of 2 mg  kg1  day1, compared with placebo, significantly
reduced the risk of IDA at 6 months (66). In the placebo group, 36%
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developed ID and 10% developed IDA, as compared with 4% and
0% in the 2-mg group. Approximately half of these infants were
mostly breast-fed during the intervention and the other half received
iron-fortified formula. No adverse effects of iron supplements were
observed with regard to infant growth, infections, or other morbid-
ity. There were significant differences in iron status between those
who had received 1 or 2 mg  kg1  day1 of iron, but there were no
significant differences in the proportion of infants with ID or IDA in
the 2 groups. When considering all dietary iron sources and iron
supplements, including compliance, it was shown that an actual
iron intake of 0.25 mg  kg1  day1 was sufficient to prevent IDA
and an intake of 1 mg  kg1  day1 prevented ID (66). In a follow-
up of this study, a significantly higher proportion of abnormal
behavioral scores at 3.5 years of age was observed in the placebo
group (89a). Using a validated questionnaire (Achenbach Child
Behavior Checklist), the prevalence of children with behavioral
scores above the US subclinical cutoff was 12.7%, 2.9%, and 2.7%
in the placebo, 1-mg, and 2-mg group, respectively, as compared
with 3.2% in a reference group of children with normal birth weight.
Adjusting for socioeconomic confounders, the risk of behavioral
problems was 4.5 times higher (95% confidence interval [CI]
1.3–15.8) in placebo-treated compared with iron-supplemented
children; however, no significant differences were observed in
cognitive scores.
Previously published guidelines recommend an iron intake of
2 to 3 mg  kg1  day1 during the first 6 months of life for preterm
infants with birth weights <1800 g (7).
The ESPGHAN CoN concludes that there is some evidence
that iron supplements at a dose of 1 to 2 mg  kg1  day1 given to
infants with marginally LBW up to 6 months of age prevents IDA,
without adverse effects, and reduces the risk for later behavioral
problems.
Older Infants (From 4 to 6 Months of Age)
Because iron stores normally become depleted at approxi-
mately 6 months of age, iron-rich complementary foods are recom-
mended. This includes meat products, iron-fortified follow-on
formulas, and other iron-fortified foods, for example, cereals.
Follow-On Formulas
During the 1990s, several randomized controlled studies
were performed, investigating the effects of different iron
content in follow-on formulas on iron status and neurodevelopment.
Gill et al (90) randomized 406 healthy infants in the United
Kingdom and Ireland to receive a low-iron (1.4 mg/L) or high-
iron (12.3 mg/L) formula from 6 to 15 months of age. Infants
receiving the high-iron formula were significantly less likely to
have low serum ferritin concentrations (<10 mg/L) at 15 months
(6% vs 22%,) but there was no difference in the incidence of anemia
(Hb <110 g/L), which was 11% vs 13%. The incidence of IDA and
dietary intakes were not reported in this study.
Stevens et al (91) randomized 92 healthy UK infants to
receive a no-added-iron formula or a formula containing 12 mg/L of
iron from 6 to 18 months of life. Most of the children were from
poorer socioeconomic groups. Throughout the study, there was no
difference in mean Hb or median serum ferritin concentrations
between groups. The proportion of infants with serum ferritin levels
(<10 mg/L) at 12 to 18 months was 8% to 25% with no significant
difference between groups. The proportion of infants with anemia
(Hb<110 g/L) at 18 months was 15% in the low-iron group and 0%
in the high-iron group, but this difference was not statistically
significant. The prevalence of IDA and dietary intakes during the
intervention were not reported.
Morley et al randomized 493 healthy UK infants to 3 inter-
ventions from 9 to 18 months of age: unmodified cow’s milk,
unfortified formula (0.9 mg/L), or iron-fortified formula (12 mg/L)
(92). At 18 months, geometric mean plasma ferritin was signifi-
cantly higher in the iron-fortified group (22 vs 13–14 mg/L).
Hemoglobin values were only available in a subgroup of 38 infants.
In that subgroup, mean Hb concentrations at 18 months were
significantly higher in the iron-fortified group compared with the
2 other groups (126 vs 119–120 g/L). The proportion with anemia
(Hb <110 g/L) at 18 months was 5% in the iron-fortified group,
11% in the unfortified group, and 32% in the cow’s-milk group, but
these differences were not statistically significant. The proportions
with ID and IDA were not reported. There was no significant
difference between groups in the primary outcome, which was
Bayley mental and psychomotor development index at 18 months of
age, tested in 428 infants. Intake data were reported in a separate
study (93), showing that the mean (SD) formula intake at 9 months
was 530 180 mL/day, corresponding to 6.2 mg/day of iron
(approximately 0.7 mg  kg1  day1) from formula in the iron-
fortified group. Similarly, formula intake at 12 months was
550 220 mL/day, corresponding to 6.6 mg/day of iron (approxi-
mately 0.55 mg  kg1  day1).
Daly et al (94) randomized 100 UK infants from a poor
socioeconomic area to receive iron-fortified formula (12 mg/L) or
unmodified cow’s milk from an average of 8 months to 18 months
of age. By 18 months, 2% of the infants in the iron-fortified group
and 33% of the infants in the cow’s-milk group were anemic
(Hb <110 g/L, P< 0.001). Average formula intake at 12 months
was 582 mL/day, corresponding to 7 mg/day of iron (approximately
0.6 mg  kg1  day1) in the iron-fortified group. In addition,
infants consumed on average of 5.3-mg/day iron from solid foods at
12 months. There was no significant difference in developmental
score (Griffiths) at 18 months, but when 85% of the children
were tested at 24 months of age, those in the iron-supplemented
group had significantly higher developmental scores (Griffiths
general quotient 102.2 vs 94.5, P¼ 0.04 for change since baseline)
(95).
Walter et al randomized 835 healthy Chilean infants with
birth weights>3 kg and no IDA at 6 months to high-iron (12 mg/L)
or low-iron (2.3 mg/L) formula from 6 to 12 months. At 12 months,
infants in the high-iron group had significantly higher serum ferritin
concentrations and a significantly lower proportion had low ferritin
(49% vs 65%); however, there was no significant difference in Hb at
12 months (125 vs 123 g/L). The proportion of IDA at 12 months
was low (2.8% vs 3.8%), with no significant difference between
groups (96). Mean (SD) formula intake during the intervention was
616 178 mL/day, corresponding to 7.4 mg/day of iron (approxi-
mately 0.8 mg  kg1  day1) in the high-iron group. The corre-
sponding iron intakes in the low-iron group were 1.4 mg/day and
0.16 mg  kg1  day1. When 473 of these children were followed up
at 10 years of age using several instruments, including the Wechsler
Intelligence Scale for Children, spatial memory, arithmetic, visual
motor integration, and motor coordination, there was a trend toward a
lower IQ in the iron-fortified group (91.5 vs 93.3, P¼ 0.06), and the
iron-fortified group had significantly lower scores with regard to
spatial memory (86.8 vs 91.4,P¼ 0.02) and visual-motor integration
(97.2 vs 99.8, P¼ 0.046) (97). Furthermore, there was a significant
interaction between initial Hb at 6 months and the intervention effects
on all developmental outcomes; children with higher 6-month Hb
concentrations (>128 g/L) showed poorer developmental outcomes
if they received iron-fortified formula, whereas those with low initial
hemoglobin levels (<105 g/L) showed better outcomes with iron-
fortified formula.
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There is some evidence that iron-fortified follow-on
formulas reduce the risk of anemia, especially when compared
with unmodified cow’s milk. There are conflicting results regarding
the possible effects of iron-fortified follow-on formulas on neuro-
development, with one study showing a positive effect in high-risk
infants (94) and another showing a negative effect in iron-replete
infants (97). The latter result is potentially alarming and requires
confirmation.
A difficulty when assessing these studies is that the intake of
follow-on formula is extremely variable because the infants also
consume other foods. Using the average intakes from these studies
(approximately 600 mL/day), an average weight of 8.8 kg at
9 months, a follow-on formula with 12 mg/L of iron will result
in an iron intake of 0.8 mg  kg1  day1, which is slightly lower
than the recommended iron intake at this age; however, iron intake
from other foods may not be negligible, as shown in the Daly et al
study. Present European follow-on formulas usually contain 10 to
12 mg/L of iron. It is possible that iron fortification to lower
concentrations may be safe and effective, but this requires further
studies.
Based on the evidence from intervention trials, experience
from present practice, and theoretical iron requirements, iron for-
tification of follow-on formulas is recommended. The European
directive (98) allows iron fortification levels of follow-on formulas
between 0.6 and 2 mg/100 kcal, corresponding to 3.6 to 14 mg/L. A
recent international expert group recommends a level of 1.1 to
1.9 mg/100 kcal, corresponding to 6.6 to 13.3 mg/L (99); however,
the ESPGHAN CoN concludes that there is not enough evidence to
determine the optimal level of fortification, and it is unclear whether
fortification to a higher level (10–14 mg/L) has any advantages.
Further studies are clearly warranted of different iron for-
tification levels of follow-on formula, including long-term follow-
up of cognitive development. Furthermore, unmodified cow’s milk
should be avoided as the main milk drink in infants up to 12 months
of age.
Meat Products and Iron-Fortified Complementary
Foods
Meat products and iron-fortified foods are the major dietary
sources of iron, and early introduction of these iron-rich comp-
lementary foods is therefore likely to be important for preventing ID
and IDA in infants.
Several studies have evaluated the effects of iron-fortified
complementary foods on iron status of older infants and toddlers. A
recent meta-analysis included 18 randomized controlled trials of iron-
fortified complementary foods, including cereals and fortified milks
(n¼ 5468 children) (100). The median anemia rate at baseline was
36%, suggesting that these were not only purely preventive but also
therapeutic trials. Mean age at inclusion was 6 to 23 months. There
was a significant effect of iron-fortified complementary foods on
hemoglobin (6.2 g/L higher than controls, 95% CI 3.4–8.9 g/L). Iron-
fortified complementary foods reduced the risk of anemia (defined as
Hb<105 or 110 g/L) by 50% (95% CI 0.33–0.75). A combination of
iron and multimicronutrient fortification was more effective than iron
fortification alone; however, these results are not directly general-
izable to the European population because most of the trials were
performed in low-income countries. Of the included trials, none
evaluated iron-fortified cereals in a European or high-income
country setting.
Jonsdottir et al (17) randomized 119 exclusively breast-fed
infants at 4 months to continue exclusive breast-feeding or to
introduce complementary foods to be given between 4 and 6 months
of age. Infants receiving complementary foods had a median iron
intake of 0.3 mg/day, corresponding to approximately 0.04 mg  kg1
 day1. At 6 months, infants who had received iron-fortified comp-
lementary foods had significantly higher serum ferritin concen-
trations (median 70 vs 44 mg/L, P¼ 0.02), but there was no
significant difference in Hb or other iron status indicators. There
was no significant difference in the proportion of infants with low
ferritin (<12 mg/L) at 6 months (10% vs 4% in complementary
feeding vs exclusive breast-feeding group, respectively, P¼ 0.44).
Only 2% of the infants were classified as IDA at 6 months, 1 in each
randomization group.
In a Danish study, 41 healthy infants were randomized to a
low-meat diet (10 g meat daily) or a high-meat diet (27 g meat daily)
from 8 to 10 months of age (101). At 10 months, Hb was signifi-
cantly higher among infants in the high-meat group (4 g/L differ-
ence, P¼ 0.008). No infant had IDA in this study.
Krebs et al randomized 88, exclusively breast-fed US infants to
receive either pureed beef or iron-fortified infant cereal as their first
complementary food from 5 to 7 months of age (102). Iron intakes
were significantly higher in the cereal group (7.2 vs 1.5 mg/day) at
7 months. At 9 months of age, there was no significant difference in
Hb or serum ferritin between groups. Forty percent of infants in the
meat group and 30% of the infants in the cereal group had serum
ferritin concentrations<12mg/L. Anemia (Hb<115 g/L—taking the
altitude of Denver, Colorado into consideration) was observed in 23%
in the meat group and 15% in the cereal group. These differences in
proportions of low ferritin or Hb were not statistically significant. The
prevalence of IDA was not reported. Bayley developmental scores up
to 12 months of age did not differ between groups.
In a Canadian study, 156 infants from low-income households
were randomized to receive iron-rich complementary foods (iron-
fortified cereals and pureed meat daily), in combination with whole
cow’s milk, or no intervention, from 6 to 12 months of age (103). At
12 months, 66% of the infants remained in the study. No significant
differences in Hb, serum ferritin, or the proportion of infants with low
serum ferritin (<10 mg/L) or anemia (Hb <110 g/L) were observed.
The authors speculated that the high iron intake from complementary
foods (average 98 g of meat daily) may be counteracted by the ad
libitum cow’s-milk intake in the intervention group (amounts not
reported). In contrast, infants in the control group were either breast-
fed or fed iron-fortified formula.
Dube et al (104) randomized 97 healthy German infants to
receive commercial baby foods with high (12%) or low (8%) meat
content from 4 to 10 months of age. Taking other complementary
foods into account, total iron intakes did not differ between groups
and there was no significant difference in Hb or serum ferritin. At
10 months, 4% had anemia (Hb <105 g/L) with no difference
between intervention groups. IDA was not reported.
In summary, there is some evidence that complementary
foods with a high meat content improve Hb. There is evidence from
1 study that a high meat intake has a similar effect on iron status as
iron-fortified cereals, even though the daily iron intake in the cereal
group was approximately 5 times higher. This is compatible with
previous studies suggesting that iron absorption is several-fold
higher from meat than from cereals (105).
Based on the evidence from intervention studies, clinical
experience, and theoretical iron requirements, the ESPGHAN CoN
recommends that iron-rich complementary foods (meat products
and/or iron-fortified foods) should be given to all infants from
6 months of age.
Iron Supplements
Exclusive breast-feeding for 4 to 6 months is recommended
by the ESPGHAN and other authorities; however, exclusive
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breast-feeding beyond 6 months has been associated with increased
risk of ID and IDA (106–108). It has therefore been suggested that
iron supplements should be recommended for infants who are
breast-fed for longer than 4 to 6 months and who do not consume
enough iron from complementary foods. Indeed, the American
Academy of Pediatrics recently suggested that iron supplements
(1 mg  kg1  day1) should be given from 4 months of age to all
exclusively breast-fed infants and to partially breast-fed infants who
receive more than half of their daily feeds as human milk (78).
According to this recommendation, iron supplements of these
infants should be continued ‘‘until appropriate iron-containing
complementary foods have been introduced’’ (78). These American
Academy of Pediatrics’ recommendations have since been ques-
tioned (109,110).
There are several published randomized intervention trials,
investigating the effects of iron supplements given to infants
between 6 and 12 months of age, but almost all of these trials
have been performed in low-income countries with a high
prevalence of anemia among infants. These trials have generally
shown that iron supplements reduce anemia, especially when
given to anemic infants (60). Only a few of these trials have
investigated the effects on neurodevelopmental outcomes: Lind
et al randomized 340 Indonesian infants to receive iron supple-
mentation (10 mg/day) or placebo from 6 to 12 months of
age. These infants were healthy and none had severe anemia
(<90 g/L), but 41% had mild anemia (Hb 90–110 g/L). At
12 months, infants receiving iron supplements had a significantly
higher psychomotor developmental scores (106 vs 103, P< 0.05).
In a Thai study, 560 infants ages 4 to 6 months were randomized
to 4 groups, receiving daily iron (10 mg), zinc, iron plus zinc, or
placebo for 6 months. In a follow-up study, no significant
differences were observed at 9 years of age in cognitive per-
formance (111); however, the prevalence of IDA during infancy
was low (3%) in this sample.
To our knowledge, there has been only 1 randomized con-
trolled trial investigating the effects of iron supplements given from
4 to 6 months of age to exclusively breast-fed infants in a European
or high-income country setting (16). In this trial, 232 Swedish and
Honduran infants were randomized into 3 groups: iron supplements
from 4 to 9 months of age, iron supplements from 6 to 9 months of
age, or no iron supplements. These infants were exclusively breast-
fed to 6 months and mainly breast-fed between 6 and 9 months. In
the Honduran subgroup, iron supplements from 4 to 6 months
significantly reduced the prevalence of IDA at 9 months from
28% to 11% (P¼ 0.006); however, in the Swedish subgroup
(n¼ 101), iron supplementation did not significantly reduce the
already low prevalence of IDA at 9 months (<3% in all groups).
Furthermore, in a secondary analysis among the Swedish infants in
this study, iron supplements resulted in lower length gain with a
difference of 0.4 cm between iron-supplemented and nonsupple-
mented infants up to 9 months of age (P¼ 0.02) (62).
There is strong evidence that iron supplementation of infants
from 4 to 6 months of age reduces the prevalence of anemia in
populations with a high prevalence of IDA in infants.
There is insufficient evidence that general iron supplement-
ation of exclusively or mainly breast-fed infants from 4 to 6 months
reduces IDA or has any other health benefits in populations with a
low prevalence of IDA.
The ESPGHAN CoN does not recommend general iron
supplementation of breast-fed European infants after the age of
4 to 6 months; however, preventive iron supplementation may be
provided on an individual basis to infants from high-risk groups
(low socioeconomic status or living in areas with high prevalence of
IDA) if the infant has a low intake of iron-rich complementary
foods.
Toddlers
Among all of the preadolescent age groups, the prevalence of
IDA is highest among toddlers. IDA in toddlers can be prevented by
ensuring adequate iron intake during the first year of life, but dietary
interventions in toddlers have also been suggested and shown to
be effective for prevention or reversal of IDA in low-income
countries (112,113); however, extremely few iron intervention trials
have been performed among toddlers in European or high-income
countries.
In a Swedish trial, 36 healthy, iron-replete toddlers were
randomized to receive iron-fortified (7.0 or 14.9 mg/L) or unforti-
fied cow’s milk from 12 to 18 months of age (114). There were no
significant effects on iron status. At 18 months, the prevalence of ID
(defined by multiple biomarkers) was low (11%). Only a single
child had IDA at 18 months and that child belonged to the iron-
fortified group.
In a New Zealand trial, 225 healthy, nonanemic 12- to
20-month-old toddlers were randomized to receive a high-meat
diet, iron-fortified milk, or unmodified cow’s milk during 5 months
(115). There was a significant increase in serum ferritin (44%,
P¼ 0.002) in the fortified milk group as compared with the meat
group (10%) and the control group (14%). Both the red meat
group and the fortified milk group had a significant positive
intervention effect with regard to serum ferritin. There were no
significant differences between the 3 groups in the proportion of
infants with low ferritin (<12 mg/L) or IDA (Hb <110 g/L in
combination with other markers). The prevalence of IDA was 3%
in all groups.
There is no evidence from randomized trials conducted in
toddlers that dietary interventions prevent ID or IDA, nor that they
have other health benefits in populations with a low IDA preva-
lence; however, as reported above, there are data from randomized
controlled trials of follow-on formulas versus unmodified cow’s
milk, extending up to 18 months of age, suggesting that a high
cow’s-milk intake (average approximately 600 mL/day) increases
the risk of IDA (92,94), and there are also data from European
epidemiological studies suggesting that an intake of unmodified
cow’s milk exceeding approximately 450 mL/day is associated with
an increased risk of ID (2,4).
The ESPGHAN CoN recommends that toddlers should
receive iron-rich foods and that an intake of >500 mL/day of
unmodified cow’s milk should be avoided. It is up to national
authorities to decide what type of iron-rich foods (eg, meat pro-
ducts, iron-fortified foods) should be encouraged in their own
country, depending on food habits, and so on.
CONCLUSIONS AND RECOMMENDATIONS
BY THE ESPGHAN CoN
These recommendations are valid for Europe and other
regions with a low general prevalence of IDA.
1. There is no evidence that iron supplementation of pregnant
women improves iron status in their offspring in a European
setting.
2. Delayed cord clamping should be considered for all newborns.
3. There is no need for general iron supplementation of healthy
European infants and toddlers of normal birth weight.
4. Formula-fed infants up to 6 months of age should receive iron-
fortified infant formula, with an iron content of 4 to 8 mg/L.
5. Marginally-low-birth-weight infants (2000–2500 g) should
receive iron supplements of 1–2 mg  kg1  day1, starting at
2 to 6 weeks of age and continuing to 6 months of age,
regardless of whether they are term or preterm.
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6. LBW infants with birth weights <2000 g should receive iron
supplements at a dose of 2 to 3 mg/kg, according to
ESPGHAN guidelines for enteral nutrition of preterm infants
(7).
7. Follow-on formulas should be iron fortified; however, there is
not enough evidence to determine the optimal iron concen-
tration in follow-on formula.
8. From the age of 6 months, all infants and toddlers should
receive iron-rich (complementary) foods, including meat
products and/or iron-fortified foods.
9. Unmodified cow’s milk should not be fed as the main milk
drink to infants before the age of 12 months and intake should
be limited to <500 mL daily in toddlers.
10. It is important to ensure that this dietary advice reaches high-
risk groups such as socioeconomically disadvantaged families
and immigrant families.
FUTURE RESEARCH DIRECTIONS
Future research directions are as follows:
1. There is a need for population-based studies of the prevalence
of ID and IDA in young European children of different ages.
2. There is a lack of sufficiently powered randomized controlled
studies of the effects of different levels of iron fortification in
infant formula and follow-on formulas. Such trials are needed to
better establish iron requirements in young children, based on
effects on neurodevelopment, growth, and other health out-
comes.
3. More studies are needed on the long-term health effects of
different iron intakes in different risk groups.
4. Novel iron status indicators such as hepcidin and reticulocyte
hemoglobin should be evaluated in children of different ages.
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